Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The ethical considerations surrounding performance enhancement versus legitimate medical treatment must be carefully considered, and healthcare providers should ensure that any use of these peptides in athletic populations is medically justified and compliant with applicable anti-doping regulations
Individual experiences vary, and results depend on many factors including diet, physical activity, and overall health
GLP-1 Receptor Pathway - Reduces hunger drive centrally (hypothalamus, brainstem) - Decreases the reward value of food (mesolimbic system) - Enhances glucose-dependent insulin secretion - Slows gastric emptying Amylin Receptor Pathway - Induces satiety through the area postrema and NTS - Activates POMC neurons (pro-satiety) and suppresses NPY/AgRP neurons (pro-hunger) in the arcuate nucleus - Additional gastric emptying delay through distinct neural circuits - Suppresses post-prandial glucagon secretion - May contribute to leptin resensitization The combination of these two pathways produces what researchers describe as broader modulation of neuroendocrine appetite control meaning amycretin hits more of the biological switches that drive eating behavior than a GLP-1-only drug can reach
Despite this exciting potential, efforts to develop an amylin-based anti-obesity therapeutic stalled owing to challenges around dosage frequency, safety and formulation
US$ 27.32
US$ 22.62
US$ 22.04
US$ 26.81
US$ 28.91
